Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial

@article{Cohen2016SafetyAE,
  title={Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial},
  author={Jeffrey A. Cohen and Douglas L. Arnold and Giancarlo Comi and Amit Bar-Or and Sheila Gujrathi and Jeffrey P. Hartung and Matt Cravets and Allan D. Olson and Paul A Frohna and Krzysztof W Selmaj},
  journal={The Lancet Neurology},
  year={2016},
  volume={15},
  pages={373-381}
}

Figures and Tables from this paper

Ozanimod in relapsing forms of multiple sclerosis: a profile of its use
TLDR
In two randomised, double-blind, phase 3 clinical trials, once-daily oral ozanimod significantly reduced annualised relapse rates and MRI lesion accumulation compared with once-weekly intramuscular interferon β-1a 30 µg.
Ozanimod for the treatment of relapsing remitting multiple sclerosis
TLDR
Ozanimod is a valuable contribution to the therapeutic armamentarium in MS, although the effect on disability progression is unclear and requires further investigations.
Ozanimod in relapsing multiple sclerosis: Pooled safety results from the clinical development program.
Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis.
TLDR
Patients with relapsing multiple sclerosis who received 75 mg of evobrutinib once daily had significantly fewer enhancing lesions during weeks 12 through 24 than those who received placebo and there was no significant effect of trial group on the change from baseline in the EDSS score.
Benefit–Risk Profile of Sphingosine-1-Phosphate Receptor Modulators in Relapsing and Secondary Progressive Multiple Sclerosis
TLDR
Long-term safety, tolerability, and persistence profiles of fingolimod should reassure clinicians that sphingosine-1-phosphate receptor modulators are likely to be suitable for the long-term treatment of multiple sclerosis.
Sphingosine-1-phosphate Receptor Modulators in Multiple Sclerosis
TLDR
While more long-term data are needed, these selective S1P receptor modulators appear to be promising options for the treatment of MS and other disorders associated with autoimmunity and inflammation.
Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study
TLDR
Ozanimod demonstrated sustained efficacy in participants continuing treatment up to 2 years and reached similar efficacy in Participants who switched from placebo; no unexpected safety signals emerged.
...
...

References

SHOWING 1-10 OF 33 REFERENCES
A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.
TLDR
Both doses of oral fingolimod improved the relapse rate, the risk of disability progression, and end points on MRI and were superior to placebo with regard to MRI-related measures.
Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.
TLDR
This trial showed the superior efficacy of oral fingolimod with respect to relapse rates and MRI outcomes in patients with multiple sclerosis, as compared with intramuscular interferon beta-1a.
Oral ponesimod in relapsing–remitting multiple sclerosis: a randomised phase II trial
TLDR
Once-daily treatment with ponesimod 10, 20 or 40 mg significantly reduced the number of new T1 Gd+ lesions and showed a beneficial effect on clinical endpoints.
A controlled trial of natalizumab for relapsing multiple sclerosis.
TLDR
In a placebo-controlled trial, treatment with natalizumab led to fewer inflammatory brain lesions and fewer relapses over a six-month period in patients with relapsing multiple sclerosis.
Fingolimod-associated macular edema
TLDR
The purpose of this review is to educate the neurologist on the etiology, clinical manifestations, diagnostic modalities, and treatment approaches in patients with FAME, and outline the key distinguishing features between FAME and optic neuritis.
Oral fingolimod (FTY720) for relapsing multiple sclerosis.
TLDR
In this proof-of-concept study, fingolimod reduced the number of lesions detected on MRI and clinical disease activity in patients with multiple sclerosis and both measures decreased in patients who switched from placebo to fingolIMod.
Long-term effects of fingolimod in multiple sclerosis
TLDR
This study provides Class IV evidence that long-term fingolimod treatment is well-tolerated and reduces relapse rates, disability progression, and MRI effects in patients with RRMS.
Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis
TLDR
Findings suggest that S1PR modulation by fingolimod in both the immune system and CNS, producing a combination of beneficial anti‐inflammatory and possibly neuroprotective/reparative effects, may contribute to its efficacy in MS.
The effect of anti-α4 integrin antibody on brain lesion activity in MS
TLDR
Short-term treatment with monoclonal antibody against α4 integrin results in a significant reduction in the number of new active lesions on MRI, and further studies will be required to determine the longer term effect of this treatment on MRI and clinical outcomes.
...
...